FMP

FMP

Enter

CORT - Corcept Therape...

photo-url-https://images.financialmodelingprep.com/symbol/CORT.png

Corcept Therapeutics Incorporated

CORT

NASDAQ

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

57.68 USD

-0.92 (-1.6%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. Joseph K. Belanoff M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advance...

CIK

0001088856

ISIN

US2183521028

CUSIP

218352102

Address

149 Commonwealth Drive

Phone

650 327 3270

Country

US

Employee

352

IPO Date

Apr 14, 2004

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

CORT Financial Summary

CIK

0001088856

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

218352102

ISIN

US2183521028

Country

US

Price

57.68

Beta

0.46

Volume Avg.

987.99k

Market Cap

6.04B

Shares

-

52-Week

20.84-61.66

DCF

82.76

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

45.78

P/B

-

Website

https://www.corcept.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest CORT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep